Woodfield Distribution Llc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Woodfield Distribution Llc Pharmaceutical Import Records from India — 3 Products, $5.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Woodfield Distribution Llc — Pharmaceutical Importer Profile (2026) | 3 Products, $5.8M Trade | TransData Nexus

Woodfield Distribution Llc

Pharmaceutical Importer · United States · Cardiovascular Focus · $5.8M Total Trade · DGFT Verified

Woodfield Distribution Llc is a pharmaceutical importer based in United States with a total trade value of $5.8M across 3 products in 1 therapeutic categories. Based on 127 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Woodfield Distribution Llc sources from 1 verified Indian supplier, with Rubicon Research Private Limited accounting for 100.0% of imports.

Woodfield Distribution Llc — Import Portfolio & Supplier Network

Woodfield Distribution Llc import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Woodfield Distribution Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Rubicon Research Private Limited	$18.1M	703	100.0%

Woodfield Distribution Llc sources from 1 verified Indian supplier across 217 distinct formulations. The sourcing is highly concentrated — Rubicon Research Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Baclofen tablets USP 10MG [1000's TAB	$760.7K	30
Sildennafil tablets USP 50MG [1000's TAB	$573.7K	30
Buspirone hydrochloride tablets USP 15MG	$387.3K	17
Potassium chloride extended-release	$338.1K	16
Buspirone hydrochloride tablets USP 10MG	$325.5K	8
40295 amiodarone hcl TAB USP 200MG	$300.0K	6
Isosorbide dinitrate tablets USP 20MG	$300.0K	6
40623 prinnidone TAB USP 50MG	$300.0K	6
40623 prinnidone TAB USP 50MG 100	$300.0K	6
40294 amiodarone hci TAB USP 200nng 60	$300.0K	6
Amiodarone hcl tablets USP 200MG	$300.0K	6
Amiodarone hcl tablets USP 200MG	$300.0K	6
Carvedilol TAB USP 25MG 500's-40622	$300.0K	6
40677 labetalol hci TAB USP 200MG 500	$292.4K	6
40664 carvedilol TAB USP 6.25MG 1000	$264.5K	6

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Amiodarone	Cardiovascular	$2.4M	48	2.1%	6
2	Isosorbide	Cardiovascular	$1.9M	49	2.6%	5
3	Carvedilol	Cardiovascular	$1.5M	30	1.5%	11

Woodfield Distribution Llc imports 3 pharmaceutical products across 1 categories into United States totaling $5.8M.

Woodfield Distribution Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Woodfield Distribution, LLC, also known as WDSrx, is a privately held company specializing in integrated third-party logistics (3PL) services for the pharmaceutical industry. Established in 2010 and headquartered in Boca Raton, Florida, WDSrx offers a comprehensive suite of services, including warehousing, fulfillment, transportation management, and cold-chain capabilities. The company caters to a diverse clientele, encompassing pharmaceutical, supplement, animal health, specialty chemical, medical device, and personal care product manufacturers.

WDSrx operates multiple temperature-regulated facilities across the United States, with locations in Florida, New Jersey, Ohio, Texas, and Nevada. These facilities are licensed to meet current Good Manufacturing Practice (cGMP), Food and Drug Administration (FDA), Drug Enforcement Administration (DEA), and other federal and state regulatory requirements, ensuring compliance for handling over-the-counter, prescription, and controlled substances.

In August 2023, WDSrx and its president, Adam Runsdorf, agreed to pay $2.475 million to resolve allegations of failing to properly account for controlled substances, highlighting the company's commitment to regulatory compliance.

2Distribution Network

WDSrx's distribution network comprises strategically located facilities across the United States, including Florida, New Jersey, Ohio, Texas, and Nevada. These facilities are equipped to handle a wide range of pharmaceutical products, including controlled substances, and are compliant with cGMP, FDA, DEA, and other regulatory standards.

The company's logistics capabilities encompass warehousing, fulfillment, transportation management, and cold-chain services, enabling efficient distribution of pharmaceutical products nationwide. WDSrx also manages e-commerce programs for direct-to-practitioner/patient and direct-to-consumer fulfillment, including platforms like Amazon FBA.

3Industry Role

WDSrx functions as a third-party logistics (3PL) provider within the pharmaceutical supply chain, offering services such as warehousing, fulfillment, transportation management, and cold-chain capabilities. The company does not engage in the direct importation or distribution of pharmaceutical products but instead provides logistical support to manufacturers and distributors.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Woodfield Distribution Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

WDSrx's import activities from India are concentrated with a single supplier, RUBICON RESEARCH PRIVATE LIMITED, accounting for all 127 shipments valued at $5.8 million. This single-source dependency may pose risks related to supply chain disruptions, such as production delays or quality control issues. However, the consistent volume and frequency of shipments suggest a stable and long-term relationship between WDSrx and RUBICON RESEARCH PRIVATE LIMITED.

2Supply Chain Resilience

The resilience of WDSrx's Indian supply chain is contingent upon the reliability of RUBICON RESEARCH PRIVATE LIMITED. The lack of backup suppliers and the high concentration of imports from a single source indicate potential vulnerabilities. Additionally, the absence of information regarding the diversity of formulations imported and the exposure to specific shipping routes further underscores the need for a more diversified and resilient supply chain strategy.

3Strategic Implications

The current sourcing pattern positions WDSrx as highly dependent on RUBICON RESEARCH PRIVATE LIMITED for its pharmaceutical imports from India. This dependency may limit the company's ability to negotiate favorable terms and could expose it to risks associated with supply chain disruptions. For Indian exporters, this presents an opportunity to become alternative suppliers to WDSrx, potentially reducing the company's reliance on a single source and enhancing supply chain resilience.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA) and the Drug Enforcement Administration (DEA) regulations for controlled substances. The marketing authorization pathway for Indian generics involves obtaining FDA approval through the Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the United States mandate that importers register with the FDA and, when applicable, the DEA for controlled substances. Good Manufacturing Practice (GMP) certificates from recognized authorities, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, or Pharmaceutical Inspection Co-operation Scheme (PIC/S), are essential for ensuring product quality and safety. Importers must also obtain wholesale distribution authorization from state regulatory agencies to operate legally.

3Quality & Labeling

Woodfield Distribution Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

WDSrx's focus on cardiovascular products, including amiodarone, isosorbide, and carvedilol, aligns with the significant demand for these medications in the U.S. market. The company's import strategy is likely driven by the need to provide a consistent supply of these essential drugs, catering to the therapeutic needs of a substantial patient population.

2Sourcing Profile

WDSrx's sourcing strategy emphasizes the importation of generic pharmaceutical formulations from India, particularly in the cardiovascular category. The company's preference for specific formulations suggests a targeted approach to meet market demand and address therapeutic needs effectively.

3Market Positioning

Based on its product mix, WDSrx serves the wholesale distribution segment of the U.S. pharmaceutical market. By importing and distributing essential cardiovascular medications, the company plays a crucial role in ensuring the availability of these drugs to healthcare providers and patients nationwide.

Seller's Guide — How to Become a Supplier to Woodfield Distribution Llc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with WDSrx, particularly in the cardiovascular product category. By offering high-quality generics that meet FDA standards, Indian exporters can fill gaps in WDSrx's current sourcing strategy, potentially reducing the company's reliance on a single supplier and enhancing supply chain resilience.

2Requirements & Qualifications

Indian exporters seeking to supply WDSrx must obtain FDA approval for their products, ensuring compliance with U.S. regulatory standards. Possessing GMP certificates from recognized authorities, such as EU GMP, WHO GMP, or PIC/S, is essential. Additionally, exporters must adhere to FDA labeling requirements and serialization mandates to facilitate market entry.

3How to Approach

To establish a relationship with WDSrx, Indian exporters should initiate contact through formal channels, presenting their product portfolios and demonstrating compliance with FDA and GMP standards. Participating in industry trade shows and networking events can also provide opportunities to engage with WDSrx representatives. Understanding the regulatory filing process and preparing for timely submissions will be crucial for successful collaboration.

Frequently Asked Questions — Woodfield Distribution Llc

What products does Woodfield Distribution Llc import from India?

Woodfield Distribution Llc imports 3 pharmaceutical products across 1 categories. Top imports: Amiodarone ($2.4M), Isosorbide ($1.9M), Carvedilol ($1.5M).

Who supplies pharmaceuticals to Woodfield Distribution Llc from India?

Woodfield Distribution Llc sources from 1 verified Indian suppliers. The primary supplier is Rubicon Research Private Limited (100.0% of imports, $18.1M).

What is Woodfield Distribution Llc's total pharmaceutical import value?

Woodfield Distribution Llc's total pharmaceutical import value from India is $5.8M, based on 127 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Woodfield Distribution Llc focus on?

Woodfield Distribution Llc imports across 1 categories. The largest: Cardiovascular (100.0%).

Get Full Woodfield Distribution Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.